VAccination to Improve Clinical outComes in Heart Failure Trial (VACC-HeFT): a Feasibility Study
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2018
Price : $35 *
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms VACC-HeFT
- 04 Sep 2018 Status changed from recruiting to completed.
- 16 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 May 2016, according to ClinicalTrials.gov record.
- 16 Dec 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.